Prohemostatic proteins for the treatment of bleeding
US-2024390467-A1 · Nov 28, 2024 · US
Single-dose administration of Factor VIIa
US9029324B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9029324-B2 |
| Application number | US-12791708-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 28, 2008 |
| Priority date | Jul 16, 2001 |
| Publication date | May 12, 2015 |
| Grant date | May 12, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a bleeding episode in a subject in need of such treatment, said method comprising administering intravenously to said subject a purified Factor VIIa equivalent, wherein said administering is in a single dose and said dose comprises a single-dose-effective amount of said Factor VIIa equivalent wherein said single-dose-effective amount comprises between 250 and 500 μg/kg Factor VIIa equivalent, and wherein, subsequent to said adminis…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
- A61K38/4846Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9029324B2 cover?
- The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
- Who is the assignee on this patent?
- Hedner Ulla, Novo Nordisk Healthcare Ag
- What technology area does this patent fall under?
- Primary CPC classification A61K38/4846. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 12 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).